First-Line Treatment of Warm Autoimmune Hemolytic Anemia
Warm autoimmune hemolytic anemia (warm AIHA) requires prompt, structured first-line treatment to raise hemoglobin and resolve hemolytic symptoms. The approach centers on an established class of immunosuppressive therapy, combined with targeted nutritional support and, in select unstable cases, transfusion support.
Treatment approach
Corticosteroid therapy is the cornerstone of initial treatment for warm AIHA, used in almost all patients. Nutritional supplementation is incorporated universally, and red blood cell transfusion is reserved for medically unstable presentations. The complete regimen — including specific agents, sequencing, tapering strategy, and transfusion criteria — is available in the full protocol.
Clinical goals
Successful therapy targets a stable hemoglobin level above 10 g/dL with a measurable rise in Hgb, and full resolution of symptoms.
References
DOI: 10.1182/hematology.2022000405
- Corticosteroids are the initial therapy for almost all patients (Table 4).
- Prednisone at 1mg/kg/d for 2 to 4 weeks until the Hgb level is over 10 is a common starting dose.
- Slow steroid tapering over 5 to 12 weeks to the lowest effective dose is then undertaken, with close monitoring (every 1-2 weeks) of Hgb, reticulocyte count, LDH, and haptoglobin.
- All patients should be supplemented with folic acid of at least 0.4mg/d and repleted with B12 and iron if so deficient.
- In medically unstable, symptomatic patients, particularly those with Hgb levels lower than 6g/dL, RBC transfusion is indicated.
- Over 85% of patients have a rise in Hgb.
- Successful therapy strives for a stable Hgb level over 10g/dL, resolution of symptoms, and transfusion independence.
View source ↗